Oncogenically active MYD88 mutations in human lymphoma

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Nature

• Publication date

  2011-02-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nature09671PMID 21179087PMCID PMC5024568
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.

  2010cited by this paper
• Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

  2010cited by this paper
• Regulation of Adaptive Immunity by the Innate Immune System

  2010cited by this paper
• Oncogenic activation of NF-kappaB.

  2010cited by this paper
• Helical assembly in the MyD88:IRAK4:IRAK2 complex in TLR/IL-1R signaling

  2010cited by this paper
• Aggressive lymphomas.

  2010cited by this paper
• TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma

  2009cited by this paper
• Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma

  2009cited by this paper
• Frequent inactivation of A20 in B-cell lymphomas

  2009cited by this paper
• New insights into the regulation of human B-cell differentiation.

  2009cited by this paper
• Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.

  2008cited by this paper
• Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

  2008cited by this paper
• Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma

  2008cited by this paper
• Stromal gene signatures in large-B-cell lymphomas.

  2008cited by this paper
• The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas.

  2008cited by this paper
• Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.

  2007cited by this paper
• Innate immune recognition of, and regulation by, DNA.

  2006cited by this paper
• A library of gene expression signatures to illuminate normal and pathological lymphoid biology

  2006cited by this paper
• Details of Toll-like receptor:adapter interaction revealed by germ-line mutagenesis.

  2006cited by this paper
• A loss-of-function RNA interference screen for molecular targets in cancer

  2006cited by this paper
• Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4.

  2006cited by this paper
• Prostate Stem Cell Antigen Is Overexpressed in Prostate Cancer Metastases

  2005cited by this paper
• Interactive Sites in the MyD88 Toll/Interleukin (IL) 1 Receptor Domain Responsible for Coupling to the IL1β Signaling Pathway*

  2005cited by this paper
• Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.

  2005cited by this paper
• Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling

  2005cited by this paper
• Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells

  2001cited by this paper
• Structural basis for signal transduction by the Toll/interleukin-1 receptor domains

  2000cited by this paper
• Characteristic pattern of chromosomal gains and losses in marginal zone B cell lymphoma detected by comparative genomic hybridization

  1997cited by this paper
• The Interleukin-1 Receptor-associated Kinase Is Degraded by Proteasomes following Its Phosphorylation*

  1997cited by this paper

• Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia.

  2026cites this paper
• Biological heterogeneity in adult IRF4‐rearranged large B‐cell lymphoma: Stratification by age and anatomical site

  2026cites this paper
• Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome.

  2026cites this paper
• Discovery of Novel, Potent, and Selective IRAK1 Inhibitors as Potential Therapeutics for Hepatocellular Carcinoma.

  2026cites this paper
• Clinical characterization and targeted genetic mutation profiling of autoimmune disease–associated B-cell lymphoma

  2026cites this paper
• Schnitzler syndrome: A deep insight into a rare medical disorder

  2026cites this paper
• Mechanisms of resistance to bruton’s tyrosine kinase inhibitors: synergistic effects of tumor microenvironment regulation and signaling pathways

  2026cites this paper
• Clinical and laboratory markers to distinguish VEXAS from Schnitzler's syndrome: data from the AIDA network registries

  2026cites this paper
• Discovery and Characterization of a First-In-Class HCK/BTK PROTAC DFCI-002-06 for the Treatment of MYD88 Mutated B Cell Malignancies.

  2026cites this paper
• Axes of biological variation in diffuse large B cell lymphoma.

  2026cites this paper
• Activation of toll-like receptors by non-coding RNAs and their fragments (Review)

  2025cites this paper
• A novel clustered-based binary grey wolf optimizer to solve the feature selection problem for uncovering the genetic links between non-Hodgkin lymphomas and rheumatologic diseases

  2025cites this paper
• Myeloid cell-targeted lipid nanoparticles for B cell lymphoma immunotherapy

  2025cites this paper
• The clinical features and outcomes of aggressive large B cell lymphoma with concomitant hemophagocytic lymphohistiocytosis at diagnosis

  2025cites this paper
• Bruton’s Tyrosine Kinase: A Potential Novel Target for Neurological Disorders

  2025cites this paper
• MYD88 mutations in clonal hematopoiesis promote inflammation and hematopoietic stem cell expansion

  2025cites this paper
• MyD88 polymerization and association to cellular membranes in a yeast heterologous model

  2025cites this paper
• Case report: Therapeutic use of bortezomib in a patient with Schnitzler syndrome

  2025cites this paper
• BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies.

  2025cites this paper
• Audit of B-cell cancer genes

  2025cites this paper
• Mutational Profiling of Korean Lymphomas and Diffuse Large B-Cell Lymphoma Subtype Classification Using Targeted Panel Sequencing.

  2025cites this paper
• Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degraders for Treating Inflammatory Diseases: Advances and Prospects.

  2025cites this paper
• Current and emerging treatment perspectives for adults with Waldenström macroglobulinemia

  2025cites this paper
• Sequence rules for a long SPOP-binding degron required for protein ubiquitylation

  2025cites this paper
• Neue Therapiestrategien beim primären ZNS-Lymphom

  2025cites this paper
• G-quadruplex and i-motif DNA structures form in the promoter of the key innate immune adaptor MYD88

  2025cites this paper
• Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression

  2025cites this paper
• MyD88 self-assembles into supramolecular filaments to amplify NF-κB signaling

  2025cites this paper
• Clonal identification and homology differentiate primary central nervous system lymphoma from non-central nervous system lymphoplasmacytic lymphoma: a case report

  2025cites this paper
• Lymphoma driver mutations at the root of somatic evolution of nerve-damaging autoantibodies in myelin associated glycoprotein neuropathy.

  2025cites this paper
• Metabolic Heterogeneity in Diffuse Large B-Cell Lymphoma Cells Reveals an Innovative Antimetabolic Combination Strategy

  2025cites this paper
• IRAK1 promotes gastric cancer progression by activating the PI3K/AKT/mTOR pathway and inducing the M2 polarization of tumor-associated macrophages

  2025cites this paper
• Cutaneous diffuse large B-cell lymphoma induces a macrophage immunosuppressive phenotype through IL-10 secretion

  2025cites this paper
• Gene Expression Profiling Provides an Improved Characterization of CD79B-Mutated Diffuse Large B-Cell Lymphomas

  2025influential citation
• Repurposing pacritinib to target MYD88‐mutated Waldenström macroglobulinaemia

  2025cites this paper
• MYD88 and CD79B Mutation Analysis in Primary Pharyngeal Diffuse Large B‐Cell Lymphomas: Expanding the MCD‐Like Subtype From the Sinonasal Region to the Upper Airway

  2025cites this paper
• The Direction of Modern Therapies in Waldenström Macroglobulinaemia

  2025cites this paper
• Detection of MYD88 L265P Mutation by Allele‐Specific Polymerase Chain Reaction in Atypical Lymphoplasmacytic Lymphoma

  2025cites this paper
• Membranous nephropathy preceding Bing-Neel syndrome: successful treatment with tirabrutinib

  2025cites this paper
• Therapy for MYD88 L265P DLBCL.

  2025cites this paper
• Clinical and Laboratory Relevance of MYD88 L265P Mutation in B-cell Neoplasm: A Focus on Diffuse Large B-cell Lymphoma Subtype

  2025influential citation
• IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy

  2025cites this paper
• Genetic alterations and their prognostic impact in marginal zone lymphoma: a meta-analysis

  2025cites this paper
• Liquid Biopsy for Enhanced Specificity in Identifying Somatic Mutations in Aggressive Non‐Hodgkin Large B‐Cell Lymphoma: A Comparative Study of Cell‐Free DNA and Formalin‐Fixed Paraffin‐Embedded Tissue

  2025cites this paper
• Genomic Taxonomy of Aggressive B-Cell Lymphoid Neoplasms.

  2025cites this paper
• HNK-1 Antibody-Based ELISA for Soluble PTPRZ: A Practical Cerebrospinal Fluid Biomarker for Glioma

  2025cites this paper
• Signalling by co-operative higher-order assembly formation: linking evidence at molecular and cellular levels

  2025cites this paper
• ImmunoMet Oncogenesis: A New Concept to Understand the Molecular Drivers of Cancer

  2025cites this paper
• Diagnostic Implications of NGS-Based Molecular Profiling in Mature B-Cell Lymphomas with Potential Bone Marrow Involvement

  2025cites this paper
• Rapid and Sensitive Detection of the MYD88 L265P Mutation for Lymphoplasmocytic Lymphoma/Waldenström's Macroglobulinemia via CRISPR‐Cas12a

  2025cites this paper
• Síndrome de Schnitzler: una mirada profunda a un trastorno médico raro

  2025cites this paper
• CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma

  2025cites this paper
• Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenström macroglobulinaemia

  2025cites this paper
• Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B‐cell lymphoma

  2025cites this paper
• Gut microbiome and lung cancer: mechanisms, interactions, and dietary interventions

  2025cites this paper
• CEACAM1 as a mediator of B-cell receptor signaling in mantle cell lymphoma

  2025cites this paper
• Favorable impact of zanubrutinib combined with R-CHOP regimen in MYD88-mutated new-diagnosed diffuse large B-cell lymphoma: a retrospective study with propensity score-matched analysis

  2025cites this paper
• Hans’s algorithm and MYD88L265P mutation may affect prognosis of primary central nervous system B-cell lymphoma

  2025cites this paper
• Gene- and immune-targeted therapy combinations using dual-matched biomarkers for patient selection

  2025cites this paper
• Overcoming CAR-T bottlenecks in high-risk DLBCL: a molecular subtyping enhancement strategy

  2025cites this paper
• The Biology of MZL subtypes: Challenge and Relevance of Classification.

  2025cites this paper
• Disruption of fibroblast MYD88 signaling promotes antitumor immunity in pancreatic ductal adenocarcinoma.

  2025cites this paper
• BTK Inhibitor Downregulates IL-17 Secretion and Enhances CD20mb Sensitivity to ABC Type Diffuse Large B-cell Lymphoma via CYLD/NF-kB Signaling Pathway

  2025cites this paper
• Feedback loops in B-cell chromatin regulation as a therapeutic target for modulating antibody production and malignancies: insights from BACH2.

  2025cites this paper
• Early signaling pathways in virus-infected cells.

  2024cites this paper
• Successful Implementation of Combined Treatment Methods for a Rare Recurrence of Waldenstrom Macroglobulinemia With Extramedullary Lesions

  2024cites this paper
• Recent Advances in IRAK1: Pharmacological and Therapeutic Aspects

  2024cites this paper
• TRAF3 loss-of-function reveals the noncanonical NF-κB pathway as a therapeutic target in diffuse large B cell lymphoma

  2024cites this paper
• Primary Large B-cell Lymphomas of Immune-Privileged Sites.

  2024cites this paper
• Genomic landscape and distinct molecular subtypes of primary testicular lymphoma

  2024cites this paper
• Evaluation of NFKB1 and MyD88 expression levels in a sample of non-Hodgkin lymphoma patients before and during chemotherapy

  2024cites this paper
• Decoding Toll-like receptors: Recent insights and perspectives in innate immunity.

  2024cites this paper
• Clinical Validation of a Targeted Next Generation Sequencing Panel for Lymphoid Malignancies.

  2024cites this paper
• Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics

  2024cites this paper
• Good clinical response following Ibrutinib treatment of a rare case of lymphoplasmacytic lymphoma secreting IgA kappa paraprotein: A case report

  2024cites this paper
• Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma

  2024cites this paper
• Lymphomas of the Vulva: A Review of the MITO Rare Cancer Group

  2024cites this paper
• Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review

  2024cites this paper
• ST2825, independent of MyD88, induces reactive oxygen species-dependent apoptosis in multiple myeloma cells

  2024cites this paper
• Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL

  2024cites this paper
• Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancer

  2024cites this paper
• A Rare Case of Non-IgM Lymphoplasmacytic Lymphoma with Unusual Lack of Immunoglobulin Light Chain Production

  2024cites this paper
• PlentiPlex™ MYD88 Waldenström lymphoma qPCR assay: A highly sensitive method for detection of MYD88 L265P mutation

  2024cites this paper
• Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma

  2024cites this paper
• Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B cell lymphoma.

  2024cites this paper
• Pseudo-uvéites

  2024cites this paper
• Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy.

  2024cites this paper
• Gut Microbiome and Cancer: From Cancer Development to Therapeutics with a Special Focus on Hepatocellular Carcinoma.

  2024cites this paper
• The impact of MYD88 and PIM1 in mature large B-cell non-Hodgkin lymphomas: Defining element of their evolution and prognosis

  2024influential citation
• NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL

  2024cites this paper
• Nomogram for predicting survival of patients with diffuse large B-cell lymphoma

  2024cites this paper
• NADPH oxidase exerts a B cell–intrinsic contribution to lupus risk by modulating endosomal TLR signals

  2024cites this paper
• Comparison of genomic alterations in Epstein–Barr virus‐positive and Epstein–Barr virus‐negative diffuse large B‐cell lymphoma

  2024cites this paper
• Research progress on the mechanism of common inflammatory pathways in the pathogenesis and development of lymphoma

  2024cites this paper
• Lymphoplasmacytic lymphoma and Waldenström Macroglobulinemia, A Decade After the Discovery of MYD88L265P.

  2024cites this paper
• DLBclass: A Probabilistic Molecular Classifier to Guide Clinical Investigation and Practice in DLBCL.

  2024cites this paper
• Molecular diagnosis of vitreoretinal lymphoma

  2024cites this paper
• Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma

  2024cites this paper
• Advances in the treatment of relapsed/refractory marginal zone lymphoma

  2024cites this paper
• Comparative analysis of somatic mutations in MYD88, CD79B, CARD11, and BTK between gastric marginal zone B-cell lymphoma of MALT and diffuse large B-cell lymphoma

  2024cites this paper